Purpose: No prior studies have addressed the performance of electronic health record (EHR) data to diagnose chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWH), in whom COPD could be more likely to be underdiagnosed or misdiagnosed, given the higher frequency of respiratory symptoms and smoking compared with HIV-uninfected (uninfected) persons.
| INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide 1 and is associated with a substantial economic bur-
den. Yet, COPD is often both underdiagnosed as well as misdiagnosed in the absence of spirometry, the gold standard to document the presence of chronic airflow limitation that is the hallmark of COPD. [1] [2] [3] [4] Spirometry is often under-utilized, including in primary care settings. [4] [5] [6] [7] [8] Under-diagnosis of COPD leaves many without needed interventions, including more aggressive efforts at smoking cessation and appropriate medications. 5, 9, 10 Misdiagnosis can result in inappropriate use of medications, with concomitant exposure to unnecessary harms from medication side effects, excess costs, and lack of intervention for the actual cause of disease.
In larger scale epidemiologic studies, determination of spirometry results to document the presence of airflow limitation consistent with COPD is not readily feasible given the expense and difficulty in obtaining these data from the electronic health record (EHR), in addition to the infrequent clinical use of spirometry. Rather, diagnoses often rest on review of billing and claims data, typically derived from the International Classification of Diseases, 9 th edition (ICD-9) codes and more recently 10 th edition (ICD-10). However, while prior studies have found variable accuracy of ICD-9 codes for COPD, few have incorporated other EHR data into algorithms for diagnosis of COPD. [11] [12] [13] [14] Our objective was to develop and validate a model using data available in the EHR, including ICD-9 codes and clinically derived data, to accurately define COPD when compared with spirometry.
We sought to compare results by HIV status, as prior studies have not addressed the performance of EHR data in people living with HIV (PLWH), in whom COPD could be more likely to be either under-diagnosed or misdiagnosed. Greater misdiagnosis could result from the frequent presence of respiratory symptoms and high prevalence of smoking in this population, particularly if spirometry is not performed to confirm the presence of COPD. [15] [16] [17] Under-diagnosis may also be more likely to occur as prior studies have shown that spirometry is under-utilized in PLWH and providers may be less aware of smoking status in their patients with HIV. 18, 19 As a result, we hypothesized that diagnoses of COPD that rely on ICD-9 codes alone in PLWH could be less accurate in PLWH. It is important to assess the performance of EHR data to diagnose COPD in PLWH and uninfected so that bias is not introduced in studies that compare differences in COPD in these populations.
We tested several models in order to allow maximum flexibility for future use and to inform performance in datasets where access to certain variables may be limited. Unlike prior studies in which cohorts were derived based on patients referred to the pulmonary function laboratory for clinical indications, 11, 13 we utilized data from a research cohort where all participants had spirometry performed to develop a predictive model, decreasing the likelihood of verification bias. We then performed a validation of these results in a separate cohort of PLWH in care in a different health system in whom spirometry had been obtained for clinical purposes.
| METHODS

| Development and validation cohorts
For our development cohort, we utilized data from the Examinations of HIV Associated Lung Emphysema (EXHALE) study, a pulmonary substudy of the Veterans Aging Cohort Study (VACS). 20 Review Boards at all locations approved this study, and participants provided written informed consent.
To assess external validity, we used data from the University of Washington (UW) HIV cohort of PLWH in clinical care, which is a participating site in the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) study. 21 We identified 294 PLWH who were enrolled at the UW site who had spirometry performed for clinical purposes between January, 2000 and October, 2015 (referred to as the UW cohort); 95 of these patients had airflow limitation on testing that was consistent with COPD.
| Data collection
In EXHALE, demographic data, laboratory values, and diagnostic codes (ICD-9) for existent medical conditions were obtained via the VA EHR
KEY POINTS
• People living with HIV infection (PLWH) have an increased risk of chronic obstructive pulmonary disease (COPD); no prior studies have evaluated whether electronic health record (EHR) data performs similarly to identify PLWH who have COPD.
• On their own, ICD-9 diagnostic codes have poor accuracy for the diagnosis of COPD compared with the gold standard of spirometry.
• However, the addition of other data available in EHRnamely age, smoking status, and prescription of inhalers for COPD-can substantially improve the ability to correctly identify individuals with COPD when compared with spirometry.
• EHR data performs similarly in PLWH and in individuals without HIV to identify COPD. Quality assessments of data are conducted at the sites prior to data transmission and prior to insertion into the central CNICS data repository by the Data Management Core. We used the medication data to identify the MDIs that were prescribed prior to spirometry for at least 90 days, as in EXHALE. CNICS participants complete a clinical assessment of patient-reported measures and outcomes on touch-screen tablets every 4 to 6 months as part of routine clinic appointments. [22] [23] [24] The CNICS clinical assessment was the source of smoking status data and was defined similarly as in EXHALE.
| Pulmonary function testing (PFT)
Research spirometry in the EXHALE study was performed pre-and post-bronchodilator according to American Thoracic Society (ATS) criteria 25, 26 
| Selection of ICD codes to defined COPD
We first compared the performance of different ICD-9 code groupings and varied the time window between ICD-9 codes and research spirometry to identify the algorithm that most accurately identified true COPD. As spirometry results were obtained prior to October 2015, ICD-10 codes were not included. Methods and results of these models are described further in the Supplementary Information. Briefly, we compared results using (1) different ICD-9 code groupings ( Figure 1 ) 4,11,27 ; (2) varying the time window to identify ICD-9 codes prior to research spirometry (ranging from ever to 1 year prior); and (3) irrespective of primary or secondary position, requiring ≥1 inpatient and/or ≥ 2 outpatient occurrences 27 versus requiring ≥1 ICD-9 codes of any type, inpatient or outpatient.
| Statistical analysis
We tested the accuracy of COPD ICD-9 codes compared with airflow limitation by spirometry (FEV1/FVC <0.70). Estimates of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and their confidence intervals were generated from logistic regression coefficients for each algorithm. 28 In adjusted models, we compared whether accuracy was different according to HIV status and other clinical factors.
As anticipated, model performance with ICD-9 codes alone was poor; thus, we generated a series of predictive models to determine whether additional variables frequently available clinically could improve accuracy to discriminate cases from non-cases of COPD. A priori, we hypothesized that age, smoking status, and MDI prescriptions of ≥90 days would be important predictors in addition to ICD-9 codes. We used Bayesian Model Averaging (BMA) as a technique to help inform variable selection, in which variables selected for model inclusion have a standard cut-off of a predicted probability of 50% or higher for being in the best model; BMA identified age and prior prescription of MDIs for model inclusion in EXHALE. Age was used as a continuous variable centered at age 50. As MDI data were missing in 35 of the EXHALE participants, these patients were considered not exposed to MDIs given the overall low prevalence of MDI prescription; results of all models were similar when these patients were excluded. Smoking status was included in additional models as ever vs never as this is more accurately obtained from the EHR than pack-years of smoking. 29, 30 In order to retain maximum flexibility for future work, we evaluated different combinations of the 4 predictors.
FIGURE 1 ICD-9 definitions of COPD
We then evaluated these same models in the UW cohort. Level of discrimination was quantified using the area under the receiver-operating 3 | RESULTS
| Characteristics of development cohort
A total of 350 participants in EXHALE completed baseline surveys and spirometry. The sample was predominantly black, male, over 50 years old and comprised mostly of former or current smokers (Table 1) .
Approximately half the participants were PLWH. Overall, 15% had an ICD-9 diagnosis of COPD, but less than half of those with an ICD-9 COPD code had a prior PFT in their VA records, without significant difference by HIV status. The prevalence of airflow limitation consistent with COPD was 20%. COPD was substantially underdiagnosed: nearly two-thirds of participants with airflow limitation did not have ICD-9 codes for COPD. Among those with airflow limitation, those who were undiagnosed tended to be less likely to have chronic cough, phlegm, or wheeze compared with participants who had an ICD-9 diagnosis (Table 1) . COPD was also misdiagnosed:
in those with COPD ICD-9 codes, only 50% had airflow limitation on spirometry.
| Validity of COPD ICD-9 codes
The best performing set of COPD ICD-9 codes included 491.x, 492.x, 493.2, and 496; excluded 490; and required 1 inpatient and/or ≥ 2 outpatient occurrences at any time prior to research spirometry (Figure 1 and eTable1 ). This resulted in the highest AUC (0.638, 95%
confidence interval [CI] 0.578-0.698), with a sensitivity of 37%, specificity of 90%, PPV of 49%, and NPV of 85%. The sensitivity, specificity, PPV, and NPV of COPD ICD-9 codes were similar in PLWH and uninfected individuals and when adjusted for other factors (Table 2 ).
| Predictive model for COPD in EXHALE
We next generated a series of predictive models to identify COPD cases using additional data from the EHR (Table 3) . Using BMA, age and prior prescription of MDIs for ≥90 days had a predicted probability of ≥50% for being in the model (Model 2). ICD-9 codes and smoking status, however, had less than a 50% predicted probability of being included in the model. Because we hypothesized that these would be important in other datasets and for flexibility in other settings, we evaluated models with different combinations of these 4 variables. All models had an AUC that was significantly better than ICD-9 codes alone (P < 0. In sensitivity analyses, we excluded short-acting beta-agonists and restricted MDIs to only long-acting COPD medications, but likely due to overall low frequency of use, the AUCs were not improved (data not otherwise shown).
| External validation in the UW cohort
Within the UW cohort (N = 4126), we identified 294 PLWH who had spirometry for clinical indications. The mean age of patients was 49 (SD 9), and 80% were ever smokers, 84% were male, 67% were white, 21% were black, and 6% were Hispanic. Similar to the prevalence in the development cohort, 27% had ICD-9 diagnoses of COPD prior to spirometry; 23% were on COPD medications. Overall, 95 (32%) had confirmed airflow limitation on spirometry; of these, 45 (47%)
had an ICD-9 code for COPD prior to spirometry. Of the 79 patients (27%) who had an ICD-9 code for COPD prior to spirometry, 45 (57%) were found to have airflow obstruction on testing.
We generated similar models to determine the accuracy to diag- 
| DISCUSSION
In this study, we found that ICD-9 codes were poor at discriminating cases from non-cases of COPD in both PLWH and uninfected populations when compared with the gold standard of spirometry to detect airflow limitation. However, when combined with or substituted for other clinical variables that are obtainable within the EHR-namely age, ever smoking, and prior prescription of at least 90 days of any MDIs used for COPD, discrimination was adequate both within the VA-based EXHALE study (AUC 0.772) and within the UW cohort of PLWH in care (AUC 0.734). These data support that EHR data can be used to identify COPD cases in PLWH and uninfected individuals with acceptable and similar accuracy in both groups when results of spirometry are not available.
Overall, we found a lower accuracy of administrative data to diagnose COPD in our VA cohort compared with an optimal AUC of 0.79 in work by Cooke et al, 11 although our results are similar to a Canadian study. 13 The study by Cooke et al consisted of a cohort of patients who had been clinically referred for pulmonary function tests within the VA with a 47% prevalence of true COPD, potentially explaining these differences. Unlike the algorithm by Cooke et al, ours includes smoking status and uses prescriptions for 90 days or more for MDIs rather than counting cannisters prescribed; in our primary approach,
we also restricted our analyses to using variables that were recorded Results given as n (%) unless otherwise indicated, excluding those with missing data for that variable. Best ICD-9 definition of COPD requires ≥1 COPD inpatient ICD-9 and/or ≥ 2 COPD outpatient ICD-9 codes ever prior to research PFT, using 491.x, 492.x, 493.2, and 496. Abbreviations: AUC = area under the receiver operating curve; CI = confidence interval; NPV = negative predictive value; PPV = positive predictive value. prior to spirometry. We found that a COPD definition that included ICD-9 codes for chronic obstructive asthma, chronic bronchitis, and emphysema-but excluded non-specific bronchitis (490)-had the best discrimination of the COPD ICD-9 code groupings. Requiring ≥1 inpatient and/or ≥ 2 outpatient ICD-9 codes for COPD in any position generally resulted in better model performance and using ICD-9 codes at any time or within 5 years prior to research spirometry compared with limiting to 1 or 2 years prior to PFT resulted in statistically significantly better AUC. This could potentially reflect a lack of clinical activity centered on COPD care for these patients at recent appointments, yet nonetheless many of these patients had true COPD. Overall, the best performing ICD-9 code algorithm had a good specificity (90%), but a poor sensitivity for COPD diagnosis (37%). Similar to other studies, 11, 13 the PPV of ICD-9 codes in our cohort was poor, although somewhat higher when restricted to ICD-9 codes within the previous 1 to 2 years (PPV ranging from 49% to 63%). Notably, we found no difference in the performance of ICD-9 codes to diagnose COPD by HIV status, despite our concern that COPD may be more likely to be misdiagnosed or underdiagnosed in PLWH. Notably, misdiagnosis of COPD did occur in approximately 50% of PLWH based on having a COPD ICD-9 code but no airflow obstruction on spirometry. Under-diagnosis of COPD was even more common: two-thirds of those who had airflow limitation in EXHALE and half of those at UW did not have a COPD ICD-9 code prior to spirometry.
Given the poor discrimination of ICD-9 codes for COPD, we evaluated several other variables that are associated with COPD to improve diagnostic accuracy. In a model that included age, ever smoking, prescription of MDIs for at least 90 days, and ICD-9 codes for COPD, overall discrimination improved to an adequate range both in our development and validation cohorts. Notably, AUCs were also adequate in models that excluded ICD-9 codes or MDIs, pointing to ways that models might be adapted to availability of local data or for different analytic purposes. This is the first study to assess the performance of EHR data in addition to standardly used ICD-9 codes to diagnose COPD in a diverse cohort that included PLWH. A major strength of this study is that we included both development and validation cohorts, and that the validation cohort consisted of a different population derived from a different health care system, increasing external generalizability.
Further, all participants in our development cohort completed spirometry and data were not based on results from clinical referrals to the pulmonary function laboratory, thereby limiting verification bias.
Additionally, we included a large sample of minority individuals from several geographic regions.
A limitation to our study was that our development sample included few women. In the UW study, 16% were women; while consistent with the HIV epidemic in the US, which is predominantly male, it limits ability to make conclusions regarding women. potentially resulting in an over-estimation of the true prevalence of airflow limitation, and we were unable to review the individual flow-volume curves to exclude maneuvers that did not meet standard ATS quality criteria. Individuals with asthma may also have been included as true COPD, but given the high prevalence of smoking in both cohorts, concomitant COPD would be clinically difficult to exclude. In addition, although we used self-reported smoking status in our models, smoking status is increasingly available in many EHR systems; we have previously validated selfreport of smoking status within the VA EHR. 30 Finally, while these results are valid to inform many ongoing studies, future work will require validation of ICD-10 codes, a process that can be informed by these analyses.
In conclusion, we found that ICD-9 codes for COPD are poor in 
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